Blog
RSS FeedPosted by Michael Wonder on 20 May 2019
Europe responding to gene therapy challenge, but picture remains fragmented
20 May 2019 - Germany, Italy and England using outcomes-based deals. ...
Posted by Michael Wonder on 15 May 2019
NHS chief hails SMA drug deal – and was that a swipe at Vertex?
15 May 2019 - Children in England with the rare muscle wasting disease spinal muscular atrophy will get access to ...
Posted by Michael Wonder on 15 May 2019
CMS issues new guidance addressing spread pricing in Medicaid, ensures Pharmacy Benefit Managers are not up-charging taxpayers
15 May 2019 - Agency issues guidance for Medicaid Managed Care and CHIP health plans that clarifies how current regulations require ...
Posted by Michael Wonder on 15 May 2019
AbbVie announces US FDA approval of Venclexta (venetoclax) as a chemotherapy-free combination regimen for previously untreated chronic lymphocytic leukaemia patients
15 May 2019 - FDA reviewed the submission under the real-time oncology review pilot program. ...
Posted by Michael Wonder on 15 May 2019
Lipocine announces Tlando NDA PDUFA action date of 9 November 2019
14 May 2019 - Lipocine today announced that the U.S.FDA has accepted its new drug application for Tlando as testosterone ...
Posted by Michael Wonder on 15 May 2019
Trump bucks his own party again. This time, it's on importing drugs from Canada.
15 May 2019 - President Donald Trump's latest plan to lower drug prices is drawing concerns from Health Secretary Alex ...
Posted by Michael Wonder on 15 May 2019
NICE recommends first ever treatment for children with rare muscle wasting condition
15 May 2019 - Children with the rare genetic disorder spinal muscular atrophy can now be treated with nusinersen after NICE ...
Posted by Michael Wonder on 15 May 2019
Cystic fibrosis drug campaign makes no progress in year
10 May 2019 - It is a year on from the delivery of more than 1,000 letters to Downing Street, ...
Posted by Michael Wonder on 15 May 2019
Homology Medicines announces FDA fast track designation for HMI-102 gene therapy development candidate for adults with PKU
14 May 2019 - Company provides details of pheNIX, the first gene therapy trial for PKU, and remains on track to ...
Posted by Michael Wonder on 15 May 2019
FDA approves Bavencio (avelumab) plus axitinib combination for patients with advanced renal cell carcinoma
14 May 2019 - Phase III study showed combination significantly lowered risk of disease progression or death by 31% and extended ...
Posted by Michael Wonder on 14 May 2019
A new study sparks a war of words over the drug industry’s commitment to research
14 May 2019 - The pharmaceutical industry spends about $1 in $5 of its revenues on research and development. ...
Posted by Michael Wonder on 14 May 2019
PHARMAC publishes list of applications to be considered by PTAC later this month
14 May 2019 - The list includes a number of medicines for patients with breast cancer. ...
Posted by Michael Wonder on 14 May 2019
Analysis of sponsor hearings on PBAC decision making
14 May 2019 - Original research conducted by Melinda Flowers, Sean Lybrand and myself has been published on-line in the ...
Posted by Michael Wonder on 14 May 2019
Cracks in the system: without a national Pharmacare strategy, who is left behind?
14 May 2019 - Lack of public or private insurance, incomplete drug coverage or just plain sky-high prices for drugs that ...
Posted by Michael Wonder on 14 May 2019
Don’t buy pharma’s lies
14 May 2019 - As universal pharmacare gets closer to reality for Canada, drug companies are ramping up their false ...
Posted by Michael Wonder on 14 May 2019
Canadian health care stuck in the ’60s, expert says
14 May 2019 - When Patty De Guia lost her leg to cancer months after giving birth to her third ...